662 related articles for article (PubMed ID: 31965064)
1. The importance of exosomal PDL1 in tumour immune evasion.
Daassi D; Mahoney KM; Freeman GJ
Nat Rev Immunol; 2020 Apr; 20(4):209-215. PubMed ID: 31965064
[TBL] [Abstract][Full Text] [Related]
2. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression.
Haile ST; Dalal SP; Clements V; Tamada K; Ostrand-Rosenberg S
J Immunol; 2013 Sep; 191(5):2829-36. PubMed ID: 23918985
[TBL] [Abstract][Full Text] [Related]
3. Nanobody against PDL1.
Li S; Jiang K; Wang T; Zhang W; Shi M; Chen B; Hua Z
Biotechnol Lett; 2020 May; 42(5):727-736. PubMed ID: 32006351
[TBL] [Abstract][Full Text] [Related]
4. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer.
Ma YF; Chen C; Li D; Liu M; Lv ZW; Ji Y; Xu J
Oncotarget; 2017 Jan; 8(5):7614-7624. PubMed ID: 27935862
[TBL] [Abstract][Full Text] [Related]
5. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
Moon EK; Langer CJ; Albelda SM
Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
[TBL] [Abstract][Full Text] [Related]
6. Programmed death ligand 1 signals in cancer cells.
Kornepati AVR; Vadlamudi RK; Curiel TJ
Nat Rev Cancer; 2022 Mar; 22(3):174-189. PubMed ID: 35031777
[TBL] [Abstract][Full Text] [Related]
7. PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responses.
Tian H; Kang Y; Song X; Xu Y; Chen H; Gong X; Zhang W; Xu Y; Xia X; Gao X; Yao W
Cancer Lett; 2020 Apr; 476():170-182. PubMed ID: 32092355
[TBL] [Abstract][Full Text] [Related]
8. A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition.
Gong C; Milberg O; Wang B; Vicini P; Narwal R; Roskos L; Popel AS
J R Soc Interface; 2017 Sep; 14(134):. PubMed ID: 28931635
[TBL] [Abstract][Full Text] [Related]
9. A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).
Kong X; Lu P; Liu C; Guo Y; Yang Y; Peng Y; Wang F; Bo Z; Dou X; Shi H; Meng J
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760188
[TBL] [Abstract][Full Text] [Related]
10. Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8⁺ T cells.
Leng C; Li Y; Qin J; Ma J; Liu X; Cui Y; Sun H; Wang Z; Hua X; Yu Y; Li H; Zhang J; Zheng Y; Wang W; Zhu J; Wang Q
Oncol Rep; 2016 Feb; 35(2):699-708. PubMed ID: 26718132
[TBL] [Abstract][Full Text] [Related]
11. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.
Havel JJ; Chowell D; Chan TA
Nat Rev Cancer; 2019 Mar; 19(3):133-150. PubMed ID: 30755690
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
13. The clinical significance of PD‑L1 in colorectal cancer (Review).
Ntomi V; Foukas P; Papaconstantinou D; Antonopoulou I; Pikoulis A; Panagiotides I; Pikoulis E; Syrigos K
Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846789
[TBL] [Abstract][Full Text] [Related]
14. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
[TBL] [Abstract][Full Text] [Related]
15. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
[TBL] [Abstract][Full Text] [Related]
16. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1.
Li H; Li CW; Li X; Ding Q; Guo L; Liu S; Liu C; Lai CC; Hsu JM; Dong Q; Xia W; Hsu JL; Yamaguchi H; Du Y; Lai YJ; Sun X; Koller PB; Ye Q; Hung MC
Gastroenterology; 2019 May; 156(6):1849-1861.e13. PubMed ID: 30711629
[TBL] [Abstract][Full Text] [Related]
17. The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer.
Tang Y; Zhang P; Wang Y; Wang J; Su M; Wang Y; Zhou L; Zhou J; Xiong W; Zeng Z; Zhou Y; Nie S; Liao Q
Front Immunol; 2020; 11():604. PubMed ID: 32322256
[TBL] [Abstract][Full Text] [Related]
18. Coinhibitory Pathways in Immunotherapy for Cancer.
Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of PD‑L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300‑mediated NF‑κB signaling.
Lucas J; Hsieh TC; Halicka HD; Darzynkiewicz Z; Wu JM
Int J Oncol; 2018 Oct; 53(4):1469-1480. PubMed ID: 30066852
[TBL] [Abstract][Full Text] [Related]
20. Combination cancer immunotherapy and new immunomodulatory targets.
Mahoney KM; Rennert PD; Freeman GJ
Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]